Detalhe da pesquisa
1.
Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Tumori
; 109(2): 173-185, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35578746
2.
Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation.
Radiother Oncol
; 175: 26-32, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35934169
3.
Recommendation for the contouring of limbic system in patients receiving radiation treatment: A pictorial review for the everyday practice and education.
Crit Rev Oncol Hematol
; 159: 103229, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33482343
4.
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Cancer Treat Rev
; 95: 102176, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33743409
5.
Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study.
Radiother Oncol
; 158: 74-82, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33639190
6.
Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy.
Tumori
; 106(1): 39-46, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31451102
7.
Prevalence of Fatigue in Head and Neck Cancer Survivors.
Ann Otol Rhinol Laryngol
; 128(5): 413-419, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30700107
8.
Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group.
Head Neck
; 41(10): 3684-3692, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31355972
9.
Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis.
Crit Rev Oncol Hematol
; 139: 75-82, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31112885
10.
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
J Cancer Res Clin Oncol
; 145(2): 393-409, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30474756
11.
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
J Cancer Res Clin Oncol
; 145(9): 2411, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31346710
12.
Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes.
Anticancer Res
; 38(3): 1671-1676, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29491101